Illumina, Inc. (NASDAQ:ILMN) Position Reduced by Advisors Asset Management Inc.

Advisors Asset Management Inc. trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 9.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,047 shares of the life sciences company’s stock after selling 107 shares during the quarter. Advisors Asset Management Inc.’s holdings in Illumina were worth $137,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. grew its position in Illumina by 1,073.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,126 shares of the life sciences company’s stock worth $16,318,000 after purchasing an additional 114,466 shares in the last quarter. NS Partners Ltd grew its holdings in shares of Illumina by 2.5% during the third quarter. NS Partners Ltd now owns 37,103 shares of the life sciences company’s stock valued at $4,839,000 after buying an additional 900 shares in the last quarter. Jennison Associates LLC raised its position in Illumina by 45.2% during the third quarter. Jennison Associates LLC now owns 288,062 shares of the life sciences company’s stock valued at $37,566,000 after buying an additional 89,663 shares during the period. Commerce Bank raised its position in Illumina by 3.5% during the third quarter. Commerce Bank now owns 6,376 shares of the life sciences company’s stock valued at $831,000 after buying an additional 217 shares during the period. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Illumina in the 3rd quarter worth about $710,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ILMN. UBS Group lifted their target price on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group increased their target price on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research report on Tuesday, November 5th. Scotiabank lowered their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a report on Thursday, August 15th. Royal Bank of Canada increased their price objective on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Finally, Stephens lifted their price objective on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Stock Down 0.1 %

ILMN stock opened at $144.15 on Friday. The stock has a market capitalization of $22.86 billion, a price-to-earnings ratio of -14.47 and a beta of 1.13. The company has a 50-day moving average of $141.88 and a two-hundred day moving average of $125.88. Illumina, Inc. has a 52-week low of $99.23 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.33 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.